BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang Q, Li X, Zhang F, Yang Q, Zhou W, Liu J. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis. Int J Med Sci 2021;18:1786-97. [PMID: 33746596 DOI: 10.7150/ijms.46811] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Ni B, Hou J. Promising therapeutic approaches for relapsed/refractory multiple myeloma. Hematology 2022;27:343-52. [PMID: 35287555 DOI: 10.1080/16078454.2022.2045724] [Reference Citation Analysis]
2 Battram AM, Bachiller M, Lopez V, Fernández de Larrea C, Urbano-Ispizua A, Martín-Antonio B. IL-15 Enhances the Persistence and Function of BCMA-Targeting CAR-T Cells Compared to IL-2 or IL-15/IL-7 by Limiting CAR-T Cell Dysfunction and Differentiation. Cancers (Basel) 2021;13:3534. [PMID: 34298748 DOI: 10.3390/cancers13143534] [Reference Citation Analysis]